Osteoarthritis
Osteoarthritis
Osteoarthritis (OA) is the most common cause of disability in older adults. It is characterised by joint pain and/or joint dysfunction, and high interpatient variability. Until recently, treatment has focussed only on symptom control, meaning that the condition worsens over time, often leading to arthroplasty. A growing understanding of the pathophysiological processes underlying the condition have elucidated novel therapeutic targets, including inflammatory cytokines, matrix-degrading enzymes, mTOR signalling pathways and the Wnt pathway. Repurposing existing drugs such as metformin and statins for the treatment of OA is also being explored. Personalized OA therapy is the ultimate goal, with recent advances in
phenotype classification and numerous emerging targeted therapies offering hope for the future.
Our supporting partners do not constitute an endorsement of the content on this page.
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Nominated Future Leader, Dr Tom Appleton, shares insights into his career, osteoarthritis research, and the role of immunology in shaping future OA treatments. In this interview, Dr Appleton discusses the importance of early intervention, the impact of synovial macrophage dysfunction, and emerging therapies that could revolutionize rheumatology. His work bridges clinical care and research to drive innovation in osteoarthritis management and autoimmune disease.
Osteoarthritis is increasingly recognised as a heterogeneous disease with diverse clinical phenotypes and molecular endotypes. In this expert Q&A, Professor Ali Mobasheri discusses how precision medicine—through clinical phenotyping and molecular endotyping—can guide targeted therapies, accelerate the development of disease-modifying treatments, and transform OA management into a personalised, proactive approach that improves patient outcomes.
At the 2025 WCO-IOF-ESCEO congress, Professor Philip Conaghan presented the safety and efficacy findings from the phase 2 study of LEVI-04 for the treatment of adults with knee osteoarthritis. LEVI-04 is a first-in-class, NT-3 inhibitor, which works by targeting the inflammatory pathways involved in joint degeneration and selectively inhibiting pro-inflammatory cytokines.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
